Key result
Factor Xa inhibitors are discussed as an alternative to vitamin K antagonists for stroke prevention in atrial fibrillation, though this abstract reports no quantitative results.
Why the study?
Do factor Xa inhibitors prevent cerebral or systemic embolism compared to vitamin K antagonists in patients with atrial fibrillation?
Systematic Review
Do factor Xa inhibitors prevent cerebral or systemic embolism compared to vitamin K antagonists in patients with atrial fibrillation?
Factor Xa inhibitors represent a new class of anticoagulants with potential pharmacological and practical advantages over vitamin K antagonists for stroke prevention in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Factor Xa inhibitors discussed as alternatives without quantitative data; leaves embolism prevention efficacy open and warrants randomized trials.
A trial fibrillation (AF) is the most common type of arrhyth- mia in adults and becomes more common with increased age.Management of people with AF aims at preventing thromboembolic complications, and anticoagulant treatment with vitamin K antagonists (VKAs) has been the therapy of choice for many decades.A new class of anticoagulants, the factor Xa inhibitors, seems to have several pharmacological and practical advantages over VKAs, and some have recently been approved by regulatory authorities in the United States and Europe for stroke prevention in people with AF.
No takes yet. Share an insight, caveat, or question.
Slot et al. (2013) conducted a systematic review in Atrial Fibrillation. Factor Xa inhibitors vs. Vitamin K antagonists (VKAs) was evaluated on Cerebral or systemic embolism. Factor Xa inhibitors are discussed as an alternative to vitamin K antagonists for stroke prevention in atrial fibrillation, though this abstract reports no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: